Login to Your Account

Financings Roundup

Wednesday, January 25, 2012
• ChemoCentryx Inc., of Mountain View, Calif., set a price range for its proposed initial public offering, in which it aims to sell 4 million shares priced between $14 and $16. At the midpoint, the offering would bring in $60 million in gross proceeds. ChemoCentryx filed an S-1 last year, hoping to raise about $69 million to support multiple clinical programs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription